Integrins and cardiovascular disease

Cellular and Molecular Life Sciences

Volumn 54, Issue 6, 1998, Pages 502-513

  Clemetson, K J ^a   Clemetson, J M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Atherosclerosis; Endothelial cells; Inhibitors; Integrins; Leukocytes; Platelets; Smooth muscle cells; Thrombosis

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL INTERACTION; EMBOLISM; HUMAN; PROPHYLAXIS; THROMBOCYTE ACTIVATION; THROMBOGENESIS;

ARTERIOSCLEROSIS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INTEGRINS; LEUKOCYTES; MONOCYTES; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 0031814839     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050179     Document Type: Article

References (88)

1. Physician's Health Study. (1989) Physician's health study: aspirin and primary prevention of coronary heart disease. N. Engl. J. Med. 321: 1825-1828
2. Goodnight S. H. (1995) Antiplatelet therapy with aspirin: from clinical trials to practice. Thromb. Haemost. 74: 401-405
3. Shattil S. J. (1995) Function and regulation of the beta3 integrins in hemostasis and vascular biology. Thromb. Haemost. 74: 149-155
4. Clark E. A. and Brugge J. S. (1995) Integrins and signal transduction pathways: the road taken. Science 268: 233-239
5. Shattil S. J. and Ginsberg M. H. (1997) Integrin signaling in vascular biology. J. Clin. Invest. 100: S91-95
6. Longhurst C. M. and Jennings L. K. (1998) Integrin mediated signal transduction. Cell. Mol. Life Sci. 54: 514-526
7. Nurden A. T. and Caen J. P. (1974) An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br. J. Haematol. 28: 253-260
8. George J. N., Caen J. P. and Nurden A. T. (1990) Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 75: 1383-1395
9. Coller B. S., Peerschke E. I., Scudder L. E. and Sullivan C. A. (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and or IIIa. J. Clin. Invest. 72: 325-338
10. Ruoslahti E, and Pierschbacher M. D. (1986) Arg-Gly-Asp: a versatile cell recognition signal. Cell 44: 517-518
11. Topol E. J., Ferguson J. J., Weisman U. F., Tcheng J. E., Ellis S. G., Kleiman N. S. et al. (1997) Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb IIIa Inhibition for Prevention of Ischemic Complication. JAMA 278: 479-484
12. Lincoff A. M., Califf R. M., Anderson K. M., Weisman H. F., Aguirre F. V., Kleiman N. S. et al. (1997) Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7F3 in Preventing Ischemic Complications. J. Am. Coll. Cardiol. 30: 149-156
13. Simon D. I., Xu H., Ortlepp S., Rogers C. and Rao N. K. (1997) 7E3 monoclonal antibody directed against the platelet glycoprotein IIb IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler. Thromb. Vasc. Biol. 17: 528-535
14. Scarborough R. M., Naughton M. A., Teng W., Rose J. W., Phillips D. R., Nannizzi L, et al. (1993) Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. 268: 1066-1073
15. Suehiro K., Smith J. W. and Plow E. F. (1996) The ligand recognition specificity of beta3 integrins. J. Biol. Chem. 271: 10365-10371
16. Theroux P. (1997) Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am. Heart J. 134: S62-70
17. Kereiakes D. J., Essell J. H., Abbottsmith C. W., Broderick T. M. and Runyon J. P. (1996) Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am. J. Cardiol. 78: 1161-1163
18. Berkowitz S. D., Harrington R. A., Rund M. M. and Tcheng J. E. (1997) Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 95: 809-813
19. Handagama P., Scarborough R. M., Shuman M. A. and Bainton D. F. (1993) Endocytosis of fibrinogen into megakaryocyte and platelet α-granules is mediated by alphaIIb beta3 (glycoprotein IIb-IIIa). Blood 82: 135-138
20. Morgenstern E., Ruf A. and Patscheke H. (1992) Transport of anti-glycoprotein IIb IIIa-antibodies into the alpha-granules of unstimulated human blood platelets. Thromb. Haemost. 67: 121-125
21. Coller B. S., Seligsohn U., West S. M., Scudder L. F. and Norton K. J. (1991) Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia: evidence consistent with specific roles for glycoprotein IIb IIIa and alpha v beta 3 integrins in platelet protein trafficking. Blood 78: 2603-2610
22. Handagama P. J., Amrani D. L. and Shuman M. A. (1995) Endocytosis of fibrinogen into hamster megakaryocyte alpha granules is dependent on a dimeric gamma A configuration. Blood 85: 1790-1795
23. Diaz-Gonzalez F., Forsyth J., Steiner B. and Ginsberg M. H. (1996) Trans-dominant inhibition of integrin function. Mol. Biol. Cell. 7: 1939-1951
24. Weiss E. J., Bray P. F., Tayback M., Schulman S. P., Kickler T. S., Becker L. C. et al. (1996) A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis [see comments]. N. Engl. J. Med. 334: 1090-1094
25. Hato T., Minamoto Y., Fukuyama T. and Fujita S. (1997) Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am. J. Cardiol. 80: 1222-1224
26. Corral J., Gonzalez-Conejero R., Rivera J., Iniesta J. A., Lozano M. L. and Vicente V. (1997) HPA-1 genotype in arterial thrombosis role of HPA-1b polymorphism in platelet function. Blood Coagul. Fibrinolysis 8: 284-290
27. Carter A. M., Ossei-Gerning N., Wilson I. J. and Grant P. J. (1997) Association of the platelet P1(A) polymorphism of glycoprotein IIb IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 96: 1424-1431
28. Lasne D., Krenn M., Pingault V., Arnaud F., Fiessinger J. N., Aiach M. et al. (1997) Interdonor variability of platelet response to thrombin receptor activation: influence of P1A2 polymorphism. Br. J. Haematol. 99: 801-807
29. Murata M., Matsubara Y., Kawano K., Zama T., Aoki N., Yoshino H. et al. (1997) Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 96: 3281-3286
30. Kunicki T. J., Orchekowski R., Annis D. and Honda Y. (1993) Variability of integrin alpha2 beta1 activity on human platelets. Blood 82: 2693-2703
31. Kunicki T. J., Kritzik M., Annis D. S. and Nugent D. J. (1997) Hereditary variation in platelet integrin alpha2 beta1 density is associated with two silent polymorphisms in the alpha2 gene coding sequence. Blood 89: 1939-1943
32. Kehrel B., Balleisen L., Kokott R., Mesters R., Stenzinger W., Clemetson K. J. et al. (1988) Deficiency of intact thrombospondin and membrane glycoprotein 1a in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 71: 1074-1078
33. Nieuwenhuis H. K., Akkerman J. W., Houdijk W. P. and Sixma J. J. (1985) Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 318: 470-472
34. Santoro S. A. and Zutter M. M. (1995) The alpha 2 beta 1 imegrin: a collagen receptor on platelets and other cells. Thromb. Haemost. 74: 813-821
35. Wayner E. A., Carter W. G., Piotrowicz R. S. and Kunicki T. J. (1988) The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa. J. Cell Biol. 107: 1881-1891
36. Hindriks G., Ijsseldijk M. J., Sonnenberg A., Sixma J. J. and de Groot P. G. (1992) Platelet adhesion to laminin: role of Ca2+ and Mg2+ ions, shear rate and platelet membrane glycoproteins. Blood 79: 928-935
37. Coller B. S. (1995) The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb IIIa receptors as antithrombotic therapy. Eur. Heart J. 16 Suppl. L: 11-15
38. Coller B. S., Peerschke E. I., Scudder L. E. and Sullivan C. A. (1983) Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 61: 99-110
39. Coller B. S., Folts J. D., Scudder L. E. and Smith S. R. (1986) Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb IIIa receptor in an experimental animal model. Blood 68: 783-786
40. Huang T.-F. (1998) What have snakes taught us about integrins? Cell. Mol. Life Sci. 54: 527-540
41. Pierschbacher M. D. and Ruoslahti E. (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309: 30-33
42. Tamkun J. W., DeSimone D. W., Fonda D., Patel R. S., Buck C., Horwitz A. F. et al. (1986) Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 46: 271-282
43. Gehlsen K. R., Argraves W. S., Pierschbacher M. D. and Ruoslahti F. (1988) Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J. Cell Biol. 106: 925-930
44. Phillips D. R. and Scarborough R. M. (1997) Clinical pharmacology of eptifibatide. Am. J. Cardiol. 80: 11B-20B
45. Callahan J. F., Bean J. W., Burgess J. L., Eggleston D. S., Hwang S. M., Kopple K. D. et al. (1992) Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists. J. Med. Chem. 35: 3970-3972
46. Timm U., Zumbrunnen R., Erdin R., Singer M. and Steiner B. (1997) Oral platelet aggregation inhibitor Ro 48 3657: determination of the active metabolite and its prodrug in plasma and urine by high-performance liquid chromatography using automated column switching. J. Chromatogr. B Biomed. Sci. Appl. 691: 397-407
47. Phillips D. R., Teng W., Arfsten A., Nannizzi-Alaimo L., White M. M., Longhurst C. et al. (1997) Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 96: 1488-1494
48. Coller B. S. (1997) Monitoring platelet GP IIa/IIIb antagonist therapy. Circulation 96: 3828-3832
49. Engleman V. W., Nickols G. A., Ross F. P., Horton M. A., Griggs D. W., Settle S. L. et al. (1997) A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo [see comments]. J. Clin. Invest. 99: 2284-2292
50. Clezardin P. (1998) Recent insights into the role of integrins in cancer metastasis. Cell. Mol. Life Sci. 54: 541-548
51. Goodnight S. H. (1996) Aspirin therapy for cardiovascular disease. Curr. Opin. Hematol. 3: 355-360
52. Gent M., Blakely J. A., Easton J. D., Ellis D. J., Hachinski V. C., Harbison J. W. et al. (1989) The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1: 1215-1220
53. CAPRIE. (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348: 1329-1339
54. Gregorini L. and Marco J. (1997) Ticlopidine and aspirin interactions. Heart 77: 11-12
55. Polgar J., Eichler P., Greinacher A. and Clemetson K. J. (1998) Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 91: 549-554
56. Smith P. E., Maclennan K. and Darlington C. L. (1996) The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J. Ethnopharmacol. 50: 131-139
57. Clemetson K. J. (1997) Platelet GPIb-V-IX complex. Thromb. Haemost. 78: 266-270
58. Lopez J. A. and Dong J. F. (1997) Structure and function of the glycoprotein Ib-IX-V complex. Curr. Opin. Hematol. 4: 323-329
59. Moroi M. and Jung S. M. (1997) Platelet receptors for collagen. Thromb. Haemost. 78: 439-444
60. Clemetson K. J. (1995) Platelet activation: signal transduction via membrane receptors. Thromb. Haemost. 74: 111-116
61. Luscinskas F. W. and Lawler J. (1994) Integrins as dynamic regulators of vascular function. FASEB. J. 8: 929-938
62. Senger D. R., Claffey K. P., Benes J. E., Perruzzi C. A., Sergiou A. P. and Detmar M. (1997) Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc. Natl. Acad. Sci. USA 94: 13612-13617
63. Christofidou-Solomidou M., Bridges M., Murphy G. F., Albelda S. M. and DeLisser H. M. (1997) Expression and function of endothelial cell alpha v integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras. Am. J. Pathol. 151: 975-983
64. Keenan R. M., Miller W. U., Kwon C., Ali F. E., Callahan J. F., Calvo R. R. et al. (1997) Discovery of potent nonpeptide vitronectin receptor (alphav beta3) antagonists. J. Med. Chem. 40: 2289-2292
65. Dickeson S. K. and Santoro S. A. (1998) Ligand recognition by the I domain-containing integrins. Cell. Mol. Life Sci. 54: 556-566
66. Enenstein J. and Kramer R. H. (1994) Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J. Invest. Dermatol. 103: 381-386
67. Choi E. T., Engel L., Callow A. D., Sun S., Trachtenberg J., Santoro S. et al. (1994) Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J. Vasc. Surg. 19: 125-134
68. Van der Vieren M., Le Trong H., Wood C. L., Moore P. F., St. John T., Staunton D. E. et al. (1995) A novel leukointegrin, alphad beta2, binds preferentially to ICAM-3. Immunity 3: 683-690
69. Takahashi M., Ikeda U., Masuyama J., Kitagawa S., Kasahara T., Saito M. et al. (1994) Involvement of adhesion molecules in human monocyte adhesion to and transmigration through endothelial cells in vitro. Atherosclerosis 108: 73-81
70. Nie Q., Fan J., Haraoka S., Shimokama T. and Watanabe T. (1997) Inhibition of mononuclear cell recruitment in aortic intima by treatment with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies in hypercholesterolemic rats: implications of the ICAM-1 and LFA-1 pathway in atherogenesis. Lab. Invest. 77: 469-482
71. Gray J. L. and Shankar R. (1995) Downregulation of CD11b and CD18 expression in atherosclerotic lesion-derived macrophages. Am. Surg. 61: 674-679
72. Yokota T. and Hansson G. K. (1995) Immunological mechanisms in atherosclerosis. J. Intern. Med. 238: 479-489
73. Elemer G. S. and Edgington T. S. (1994) Monoclonal antibody to an activation neoepitope of alpha M beta 2 inhibits multiple alpha M beta 2 functions. J. Immunol. 152: 5836-5844
74. Power C. A., Clemetson J. M., Clemetson K. J. and Wells T. N. (1995) Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 7: 479-482
75. Klinger M. H., Wilhelm D., Bubel S., Sticherling M., Schroder J. M. and Kuhnel W. (1995) Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int. Arch. Allergy Immunol. 107: 541-546
76. Kameyoshi Y., Schroder J. M., Christophers E. and Yamamoto S. (1994) Identification of the cytokine RANTES released from platelets as an eosinophil chemotactic factor. Int. Arch. Allergy Immunol. 104 Suppl. 1: 49-51
77. Pattison J. M., Nelson P. J., Huie P., Sibley R. K. and Krensky A. M. (1996) RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J. Heart Lung Transplant. 15: 1194-1199
78. Celi A., Lorenzet R., Furie B. and Furie B. C. (1997) Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Semin. Hematol. 34: 327-335
79. Gahmberg C. G., Valmu L., Fagerholm S., Kotovuori P., Ihanus F., Tian L. et al. (1998) Leukocyte integrins and inflammation. Cell. Mol. Life Sci. 54: 549-555
80. Hynes R. O. and Bader B. L. (1997) Targeted mutations in integrins and their ligands: their implications for vascular biology. Thromb. Haemost. 78: 83-87
81. Clemetson K. J., McGregor J. L., James E., Dechavanne M. and Lüscher E. F. (1982) Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J. Clin. Invest. 70: 304-311
82. Libby P., Egan D. and Skarlatos S. (1997) Roles of infections agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 96: 4095-4103
83. Ellis R. W. (1997) Infection and coronary heart disease. J. Med. Microbiol. 46: 535-539
84. Halme S., Syrjala H., Bloigu A., Saikku P., Leinonen M., Airaksinen J. et al. (1997) Lymphocyte responses to Chlamydia antigens in patients with coronary heart disease. Eur. Heart J. 18: 1095-1101
85. Chiu B., Viira E., Tucker W. and Fong I. W. (1997) Chlamydia pneumoniae, cytomegalovirus and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 96: 2144-2148
86. Adam E., Melnick J. L. and DeBakey M. E. (1997) Cytomegalovirus infection and atherosclerosis. Cent. Eur. J. Public Health 5: 99-106
87. Aepfelbacher M., Essler M., Huber E., Sugai M. and Weber P. C. (1997) Bacterial toxins block endothelial wound repair. Evidence that Rho GTPases control cytoskeletal rearrangements in migrating endothelial cells. Arterioscler. Thromb. Vasc. Biol. 17: 1623-1629
88. Liao W. (1996) Endotoxin: possible roles in initiation and development of atherosclerosis. J. Lab. Clin. Med. 128: 452-460